DUBLIN--(BUSINESS WIRE)--The "North America Osteoporosis Drugs Market By Route of Administration, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
The North America Osteoporosis Drugs Market is expected to witness market growth of 3.7% CAGR during the forecast period (2020-2026).
The World Health Organization reports that about 1.66 million hip fractures occur worldwide per year owing to osteoporosis. According to the National Osteoporosis Foundation, about 54 million Americans suffer from osteoporosis. The disease also has a genetic bias in that it affects more Caucasians than Asians. The incidence of the disease is lowest in the African community.
Osteoporosis is induced by low bone mass and tissue degradation, which raises the likelihood of fracture, especially in the spine and wrists. Providers depend on the development of more focused approaches, such as anabolic medications, for successful treatment of the disease. Anabolic agents promote new bone growth, enhance bone density, and increase bone mass, as well as reduce fracture incidence.
The anabolic agent developed by Radium Health for the treatment of osteoporosis in postmenopausal women and the anabolic agent developed for the treatment of osteoporosis associated with prolonged systemic glucocorticoid therapy have also been licensed by the US FDA companies such as Amgen and Astellas Pharma are now working on producing a bone-forming monoclonal antibody for the treatment medicament. In addition to product approvals, the existence of a promising medication pipeline for osteoporosis should improve the demand for osteoporosis medicines over the coming years.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Key Topics Covered
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.3 Market Scope
1.4.1 North America Osteoporosis Drugs Market, by Route of Administration
1.4.2 North America Osteoporosis Drugs Market, by Drug Class
1.4.3 North America Osteoporosis Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Osteoporosis Drugs Market by Route of Administration
3.1 North America Oral Market by Country
3.2 North America Injectable Market by Country
3.3 North America Other Route of Administration Market by Country
Chapter 4. North America Osteoporosis Drugs Market by Drug Class
4.1 North America Bisphosphonates Market by Country
4.2 North America Rank Ligand Inhibitors Market by Country
4.3 North America Parathyroid Hormone Therapy Market by Country
4.4 North America Calcitonin Market by Country
4.5 North America Other Drug Class Market by Country
Chapter 5. North America Osteoporosis Drugs Market by Country
5.1 US Osteoporosis Drugs Market
5.1.1 US Osteoporosis Drugs Market by Route of Administration
5.1.2 US Osteoporosis Drugs Market by Drug Class
5.2 Canada Osteoporosis Drugs Market
5.3 Mexico Osteoporosis Drugs Market
5.4 Rest of North America Osteoporosis Drugs Market
Chapter 6. Company Profiles
6.1 Amgen Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent Strategies and Developments
18.104.22.168 Partnerships, Collaborations and Agreements
6.2 F. Hoffmann-La Roche Ltd.
6.3 GlaxoSmithKline PLC (GSK)
6.4 Merck & Co. Inc.
6.5 Novartis AG
6.6 Pfizer Inc.
6.7 Sun Pharmaceutical Industries Ltd.
6.8 Teva Pharmaceutical Industries Ltd.
6.9 Allergan PLC
6.10 Eli Lilly & Company
For more information about this report visit https://www.researchandmarkets.com/r/j8u3g